Abstract
A monoclonal antibody (MAb), 4D5, specifically recognising an extracellular epitope of the c-ErbB-2 protein, inhibited the growth of human gastric cancer overexpressing c-ErbB-2 severe combined immunodeficient (SCID) mice. This antibody also reduced the mass of established tumours xenografted into SCID mice, whereas gastric cancer not expressing c-ErbB-2 exhibited no regression in response to 4D5 treatment. In addition, administration of 4D5 prevented colonisation of cancer cells and prolonged the survival of host SCID mice inoculated i.v. with c-ErbB-2-overexpressing tumour cells. This is the first reported study to show that treatment with a single antibody specific to c-ErbB-2 prolongs the survival of host SCID mice bearing xenotransplanted tumours.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ohnishi, Y., Nakamura, H., Yoshimura, M. et al. Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody. Br J Cancer 71, 969–973 (1995). https://doi.org/10.1038/bjc.1995.187
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.187
- Springer Nature Limited
This article is cited by
-
Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu
Breast Cancer Research and Treatment (2007)
-
Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2 –specific hammerhead ribozyme
Cancer Gene Therapy (2001)
-
Clinical development of trastuzumab in Breast Cancer
Breast Cancer (2001)
-
Tyrosine kinases and gastric cancer
Oncogene (2000)
-
H-ras-transformed NRK-52E renal epithelial cells have altered growth, morphology, and cytoskeletal structure that correlates with renal cell carcinoma in vivo
In Vitro Cellular & Developmental Biology - Animal (1999)